Alpha-Helical Peptide Ligands for Alpha-v-Beta-6 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for αvβ6-mediated diseases, such as chronic fibrosis and carcinoma, lack effective peptide antagonists with high binding affinity and specificity, necessitating the development of novel ligands that can improve treatment and imaging strategies.
Innovation Solution
Peptides with the sequence motif RGDLXXL/I, where LXXL/I is contained within an alpha helical structure, are used as antagonists, with specific secondary structures enhancing binding potency and specificity by stabilizing the RGD motif for interaction with αvβ6, and can be cyclized, linked to detectable or therapeutically active moieties for diagnostic and therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional peptide ligands are used for αvβ6, then binding affinity is achieved, but binding specificity is insufficient
Solution Approach 1:
The patent applies local quality by introducing a specific alpha-helical structure at the LXXL position of the peptide ligand, rather than uniformly modifying the entire peptide sequence. This localized structural modification at the critical binding region enhances both specificity and affinity simultaneously, as the helical structure provides precise geometric complementarity to the integrin binding site while maintaining the essential RGD motif functionality.
Solution Approach 2:
The patent changes the structural parameter of the peptide from a random coil or extended conformation to a defined alpha-helical structure at the LXXL position. This parameter change in the three-dimensional configuration of the peptide ligand enables improved interactions with the αvβ6 integrin, resolving the contradiction between specificity and affinity by optimizing the binding geometry without compromising the essential binding functions.
2Reliability
If peptide antagonists are designed without specific secondary structures, then synthesis is simpler, but binding potency is reduced
Solution Approach 1:
The patent segments the peptide ligand into distinct functional regions: an N-terminal region containing the RGD motif for initial binding, and a C-terminal region forming the alpha-helical LXXL structure for enhanced specificity. This segmentation allows each region to be optimized independently for its specific function while maintaining overall peptide stability and binding potency.
Solution Approach 2:
Instead of attempting to synthesize complex folded structures directly, the patent takes the complementary approach by designing a linear peptide sequence that naturally folds into the required alpha-helical structure upon binding to the integrin. This inversion of the design logic simplifies synthesis while achieving the desired structural functionality.
3Productivity
If existing integrin antagonists are used, then some therapeutic effect is achieved, but treatment effectiveness is insufficient
Solution Approach 1:
The patent creates a composite peptide structure combining the classic RGD motif (essential for integrin binding) with a novel alpha-helical LXXL extension (providing enhanced specificity and affinity). This composite design integrates the best features of existing antagonists while adding new structural elements that significantly improve binding characteristics, leading to enhanced treatment effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides demonstrate increased binding affinity and specificity to αvβ6, effectively inhibiting αvβ6-dependent cell adhesion and providing a basis for both therapeutic and diagnostic interventions in αvβ6-mediated diseases.
Implementation Method 1
LXXL/I is contained within an alpha helical structure
Implementation Method 2
specific secondary structures enhancing binding potency and specificity by stabilizing the RGD motif
Implementation Method 3
subsequent to ligand binding, integrins translate extracellular cues into intracellular signals
Implementation Method 4
understanding the structural basis of integrin-ligand interaction would aid design of improved integrin antagonists
Data Source
Figure 1(a)~1(c)
Figure 2(a)~2(c)
Figure 3(a)~3(c)
AI summary
AVß6 peptide ligands comprising the sequence motif RGDLXXL/I wherein LXXL/I is contained within an alpha helical structure, functional variants thereof and their nucleic acids encoding them are disclosed with their uses in the treatment and imaging of AVß6 mediated diseases.